Pyrazolopyrrolidine Derivatives and their Use in the Treatment of Disease

A compound of formula (I), or a pharmaceutically acceptable salt thereof,

• wherein
• ring C is selected from
• i.
• and ii.
• A is selected from
• B is selected from
• R3 is selected from H, methyl, ethyl, —CH2F, —CF3, isopropyl, —OH, ethoxy, methoxy, cyclopropyl, —CH2OCH3 and —CH2OH;
• R4a is selected from H, (C1-C4)alkyl, (C3-C6)cycloalkyl, —(CH2)2—OH, —(CH2)2—O—CH3, —C(O)—NH(CH3), —C(O)—N(CH3)2,
• R4b is selected from H, (C1-C4)alkyl, (C3-C6)cycloalkyl, —(CH2)2—OH, —(CH2)2—O—CH3, —(CH2)2—O—CH2—CF3, —(CH2)—CH(OH)—CF3, —C(O)—NH(CH3), —C(O)—N(CH3)2,
• R5 is H;
• R1 is selected from H, methyl, chloro and fluoro;
• R2 is selected from bromo, chloro, fluoro, —O—CF3 and —CF3;
• R2a is fluoro;
• R8 is methyl;
• R15, R16, R18 and R33 are all methoxy;
• R17 is methyl or methoxy;
• R22, R23, R26, R27, R28, R30, R32 and R33 are all methyl;
• R24 is methyl or —CHF2;
• R25 is methyl or —NR9R10;
• R29 is H or methyl;
• R31 is H, methyl or methoxy;
• R34 is H or methyl;
• R9 is H or methyl;
• R10 is H, methyl or —C(O)—(C1-C3)alkyl;
• R35 is H, methyl, —C(O)CH3 or —C(O)OCH2CH3;
• and
• * indicates the point of attachment to the remainder of the molecule;
• with the proviso that
• when ring C is i:
• A is:
• R1 is selected from methyl, chloro and fluoro,
• B is:
• R2 is chloro, fluoro or —CF3,
• and the remaining substituents are as defined herein,
• then R3 is selected from H, methyl, ethyl, —CH2F, —CF3, —OH, ethoxy, methoxy, —CH2OCH3 and —CH2OH.